GlassScriptPhysician profile
Amanda Gillespie
NPI 1477942092
$1,071.62
in general payments reported to CMS, 2019-2025
11 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2023: $347 · 2024: $289 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $305.00 | 2021-2025 | Nuplazid |
| Organogenesis INC. | $197.84 | 2021 | |
| Neurocrine Biosciences, INC. | $138.41 | 2023 | Ingrezza |
| Insmed, INC. | $111.73 | 2024 | Arikayce |
| Mylan Specialty L.P. | $106.69 | 2024 | Yupelri |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $72.26 | 2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $48.38 | 2024 | Nuedexta, Rexulti |
| Lundbeck LLC | $29.99 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $23.32 | 2025 | Gvoke Hypopen |
| Biowound Solutions, INC. | $21.70 | 2024 | Bio-Connekt |
| Ucb, INC. | $16.30 | 2023 | Nayzilam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Gillespie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.